|
|
|||
|
|||
|
|
|||
|
vantas |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
vantas Generic Name: histrelin implant Date of Approval: October 12, 2004 Company: Valera Pharmaceuticals Treatment for: Prostate Cancer The U.S vantas. Food and Drug Administration (FDA) has approved the marketing of Vantas,a long-acting implant indicated for the palliative treatment of advanced prostatecancer. Utilizing Valera's Hydron Implant technology, Vantas has been designed for thecontinuous 12-month administration of histrelin, a synthetic nonapeptide agonistof luteinizing hormone-releasing hormone (LHRH) vantas. LHRH agonists have become a mainstay in treating locally advanced and metastaticprostate cancer with the U.S vantas. market for such therapies representing over $1billion in annual sales vantas. However, this market is dominated by 4-month and shorterduration depot injections or implants, led by Lupron Depot (leuprolide acetatefor depot suspension) from TAP Pharmaceutical Products Inc vantas. and includes Zoladex(goserelin acetate implant) from AstraZeneca PLC. Valera’s Hydron Implant technology utilizes proprietary blends of hydrogelpolymers, the same technology that originally led to the formulation of softcontact lenses vantas. In addition to providing for the administration of small, butpotent amounts of therapeutics at a controlled rate for up to a year or more,this technology platform allows for the formulation of highly compact, lightweight, flexible and retrievable subcutaneous implants that can be insertedin a physician’s office with a local anesthetic vantas. Thus, Valera expects theVantas implant to offer benefits that include less patient discomfort and improvedtherapeutic compliance. |
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| vvantas vaantas vanntas vanttas vantaas vantass antas vntas vatas vanas vants vanta v antas va ntas van tas vant as vanta s vantas avntas vnatas vatnas vanats vantsa avantas thevantas vantas | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
